Alembic Pharmaceuticals has secured final approval for its abbreviated new drug application (ANDA) of Desonide Cream, 0.05% from the US Food and Drug Administration (FDA). The ANDA for the generic version of Padagis US’ Desonide Cream, 0.05% was filed by Aleor Dermaceuticals, which was merged with Alembic Pharmaceuticals. The approved product is a low potency […]
In a significant move within the pharmaceutical industry, Spanish pharmaceutical company Almirall has finalised its $550 million acquisition of five dermatology medications from Allergan’s Medical Dermatology unit in the United States. This strategic acquisition, first announced in August 2018, aims to expand Almirall’s footprint in the US dermatology market. Acquisition Details and Financial Implications The […]
